15 Best Growth Stocks to Invest in for the Next 5 Years

Page 8 of 13

6. Aytu BioPharma, Inc. (NASDAQ:AYTU)

Upside potential as of June 24, 2025: 347.76%

On Monday, Aytu BioPharma, Inc. (NASDAQ:AYTU) disclosed that it has successfully extended its lending agreement with Eclipse Business Capital LLC (“Eclipse”), offering additional working capital flexibility to support the upcoming commercial rollout of EXXUA (gepirone) extended-release tablets.

According to the agreement, the principal balance on the term loan has been raised to $13.0 million from $11.1 million, providing enhanced liquidity. Additionally, term loan maturity has been extended by 12 months to June 2029.

Just recently, Aytu BioPharma, Inc. (NASDAQ:AYTU) unveiled an exclusive agreement to commercialize EXXUA, enabling the company to enter a market of over $22 billion in prescription MDD in the United States alone. Although more than 40 million antidepressants were prescribed in the USA in 2024, significant unmet needs still exist, mainly due to the intolerable side effects associated with existing treatments. As the clinical trials with around 5,000 patients suggest, EXXUA has exhibited better performance in depression symptoms.

Aytu BioPharma, Inc. (NASDAQ:AYTU) is a Colorado-based pharmaceutical company that focuses on novel therapeutics in the United States and internationally. The core products of the company include prescription products for people living with attention deficit hyperactivity disorder (ADHD) and pediatric prescription products. With an emphasis on patient access, the company adopts bold and innovative strategies.

Page 8 of 13